AtriCure (NASDAQ:ATRC) Insider Sells $239,861.60 in Stock

AtriCure, Inc. (NASDAQ:ATRC) insider Justin Noznesky sold 6,182 shares of the company’s stock in a transaction dated Wednesday, July 29th. The stock was sold at an average price of $38.80, for a total transaction of $239,861.60. Following the sale, the insider directly owned 100,219 shares in the company, valued at $3,888,497.20. This represents a 5.81% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this link.

AtriCure Stock Performance

NASDAQ ATRC opened at $37.76 on Friday. AtriCure, Inc. has a 1-year low of $25.36 and a 1-year high of $43.18. The company has a 50 day moving average of $31.10 and a 200-day moving average of $31.34. The company has a current ratio of 4.22, a quick ratio of 3.18 and a debt-to-equity ratio of 0.14. The firm has a market cap of $1.92 billion, a price-to-earnings ratio of 179.82 and a beta of 1.24.

AtriCure (NASDAQ:ATRC) last announced its earnings results on Thursday, July 23rd. The medical device company reported $0.18 EPS for the quarter. The business had revenue of $153.60 million for the quarter, compared to the consensus estimate of $151.80 million. AtriCure had a return on equity of 2.34% and a net margin of 1.85%.During the same period in the previous year, the business earned ($0.13) EPS. AtriCure has set its FY 2026 guidance at 0.240-0.320 EPS. On average, equities analysts forecast that AtriCure, Inc. will post 0.2 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of equities analysts have commented on the company. UBS Group reduced their price objective on AtriCure from $55.00 to $50.00 and set a “buy” rating on the stock in a research note on Tuesday. Citigroup reaffirmed a “market outperform” rating on shares of AtriCure in a report on Tuesday, July 21st. Raymond James Financial set a $52.00 price target on shares of AtriCure in a research report on Tuesday, July 21st. Canaccord Genuity Group increased their price objective on shares of AtriCure from $53.00 to $55.00 and gave the stock a “buy” rating in a report on Wednesday, May 6th. Finally, Weiss Ratings upgraded shares of AtriCure from a “sell (e+)” rating to a “sell (d+)” rating in a research report on Tuesday. Two research analysts have rated the stock with a Strong Buy rating, six have assigned a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus target price of $48.50.

Institutional Investors Weigh In On AtriCure

Several hedge funds and other institutional investors have recently made changes to their positions in the company. Geneos Wealth Management Inc. bought a new stake in shares of AtriCure during the second quarter worth $37,000. Harbor Investment Advisory LLC bought a new position in AtriCure in the second quarter valued at about $40,000. Smartleaf Asset Management LLC boosted its holdings in AtriCure by 59.8% in the fourth quarter. Smartleaf Asset Management LLC now owns 1,146 shares of the medical device company’s stock valued at $46,000 after acquiring an additional 429 shares during the last quarter. Fifth Third Bancorp acquired a new stake in AtriCure in the first quarter worth about $51,000. Finally, Global Retirement Partners LLC acquired a new stake in AtriCure in the fourth quarter worth about $73,000. 99.11% of the stock is owned by institutional investors and hedge funds.

Key Stories Impacting AtriCure

Here are the key news stories impacting AtriCure this week:

• Positive Sentiment: AtriCure’s recent second-quarter results exceeded expectations, with earnings per share of $0.18 versus the $0.13 analyst estimate and revenue of $153.6 million versus $151.8 million expected. The company also improved from a year-ago loss, supporting its growth and profitability outlook. AtriCure second-quarter results presentation
• Positive Sentiment: UBS lowered its price target from $55 to $50 but retained a Buy rating. The revised target still indicates meaningful potential upside and suggests the analyst remains constructive on AtriCure’s medical-device business. UBS AtriCure price target report
• Neutral Sentiment: Options-market coverage points to the possibility of a significant upcoming move in ATRC, but the available information does not establish whether traders are positioning for a rise or decline. Elevated options activity could contribute to short-term volatility. AtriCure options activity article
• Neutral Sentiment: New share-registration filings may give AtriCure additional financing flexibility. However, investors may monitor the filings for potential future share issuance and dilution. AtriCure share registration article
• Negative Sentiment: Insiders sold approximately $1.42 million of AtriCure shares. Director Sven Wehrwein reduced his position by about 38%, while insiders Justin J. Noznesky and Vinayak Doraiswamy each sold roughly 6% of their holdings. The clustered selling may weigh on sentiment, particularly after ATRC’s strong advance toward its 52-week high. AtriCure insider selling report

About AtriCure

AtriCure, Inc is a medical device company focused on the development, manufacture and marketing of innovative therapies to treat atrial fibrillation (AF) and related conditions. Founded in 2000 and headquartered in Mason, Ohio, AtriCure has established itself as a leader in surgical ablation devices designed to interrupt the errant electrical pathways that cause AF. The company’s solutions are used by cardiac surgeons and electrophysiologists to reduce the risk of stroke and improve patient outcomes in the treatment of both paroxysmal and persistent AF.

The company’s product portfolio centers on its Synergy Surgical Ablation System, which delivers controlled radiofrequency energy in a minimally invasive format, and the cryoICE Cryoablation System, which offers an alternative ablation modality using precise freezing techniques.